Company Filing History:
Years Active: 1989-1996
Title: Dennis P. Smith: Innovator in Biotech
Introduction
Dennis P. Smith is a notable inventor based in Indianapolis, IN (US). He has made significant contributions to the field of biotechnology, particularly in the development of innovative receptor proteins and expression control sequences. With a total of 2 patents, his work has implications for both research and practical applications in the industry.
Latest Patents
Dennis P. Smith's latest patents include the invention of the porcine vasoactive intestinal peptide receptor. This invention provides the porcine pVIP receptor protein and includes DNA compounds encoding the pVIP receptor, recombinant DNA cloning, and expression vectors. Additionally, it outlines methods for producing the pVIP receptor in various systems and using the disclosed DNA sequences as probes to isolate and characterize pVIP receptors from other species. Another significant patent involves novel expression control sequences that enhance the transcription of DNA. These sequences are designed for the expression of structural genes encoding bovine growth hormone derivatives on recombinant DNA expression vectors, functioning effectively in both Gram-positive and Gram-negative organisms.
Career Highlights
Dennis P. Smith is currently employed at Eli Lilly and Company, where he continues to advance his research and development efforts. His work at Eli Lilly has positioned him as a key player in the biotechnology sector, contributing to the company's innovative projects.
Collaborations
Throughout his career, Dennis has collaborated with esteemed colleagues, including Hansen M. Hsiung and Xing-Yue Zhang. These partnerships have fostered a collaborative environment that enhances the quality and impact of their research.
Conclusion
Dennis P. Smith's contributions to biotechnology through his patents and work at Eli Lilly and Company highlight his role as an influential inventor in the field. His innovative approaches to receptor proteins and expression control sequences continue to shape advancements in biotechnology.